What is Metanova and its vision for drug discovery

In this Subnet Session, we talk with Michaela Bazo, CEO of Metanova (SN68) — the first decentralized drug screening platform on Bittensor.

We dig into how Metanova is reshaping pharma’s $2.6B, 10-year funnel with a token-incentivized AI network that screens molecules faster, cheaper, and with real novelty. We cover everything from miner incentives to big pharma partnerships, behavioral drugs to decentralized R&D, and why alpha-backed screening might become biotech’s new backbone.

If you’re into deep tech, biotech disruption, or trillion-dollar TAMs — this one’s essential.